The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life. They make good sense for conservative portfolios looking for income and growth…
With oil plunging, and the market reeling from what should prove to be extremely good news for consumers, many investors are in a quandary over which path to take for 2016.
Wednesday's top analyst upgrades, downgrades and initiations include Agilent, CSC, Intel, Jabil Circuit, Kinder Morgan, Nasdaq, Square and Yahoo.
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Monday's top analyst upgrades, downgrades and initiations include Abbott Labs, Bluebird Bio, Chipotle, Eli Lilly, Ferrari and Wells Fargo.
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia and Rackspace.
Despite the howling from political candidates trying to make the top drug-makers their whipping boy in populist campaign efforts, the need and demand for pharmaceuticals will only continue. This is especially the case…
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Monday's top analyst upgrades, downgrades and initiations include Best Buy, CA, Deere, Eli Lilly, Ferrari, Netflix, Oracle and Salesforce.com.
24/7 Wall St. screened the Merrill Lynch research universe for pharmaceutical stocks paying solid dividends that are rated Buy, and found four outstanding companies.
Eli Lilly reported mixed third-quarter financial results on Thursday before the markets opened.
Chris Lange Eli Lilly is scheduled to report its third-quarter earnings before the markets open on Thursday.
Chris Lange While there were many winners, last week brought a lot of truly bad news or bad reactions for some of the large cap stocks in the market.
Eli Lilly is suffering after bad news about its evacetrapib for high-risk atherosclerotic cardiovascular disease.
Jon C. Ogg 